Abstract
In this concluding chapter‚ I present the overall argument of this book. My discussion in this book situates human involvement in clinical drug trials in the institutional and sociopolitical, socioeconomic , and sociocultural context that shapes human participation in medical research. This approach has been useful in developing a nuanced understanding of the policy context and the experiences of healthy volunteers in phase I commercial clinical drug trials. Contextualizing the topic in this manner brings about an understanding of healthy volunteers as subjects capable of resisting and negotiating complex and often conflicting socioeconomic and sociopolitical milieus in clinical drug trials. In this chapter‚ I review the discussion generated so far on healthy volunteering in the UK , and I draw out the implications of the research. These reviews center on the adequacy of existing regulatory structures in protecting healthy volunteers, and how risk in clinical drug trials is perceived by the actors.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abadie, R. (2010). The professional guinea pig: Big pharma and the risky world of human subjects. London: Duke University Press.
Albertson Fineman, M. (2008). The vulnerable subject: Anchoring equality in the human condition. Yale JL & Feminism, 20, 1.
Back, L. (2015). Why everyday life matters: Class, community and making life livable. Sociology, 49(5), 820–836.
Bloor, M. (1995). The sociology of HIV transmission. London: Sage.
Cooper, M., & Waldby, C. (2014). Clinical labor: Tissue donors and research subjects in the global bioeconomy. Duke University Press.
Elliott, C. (2008). Guinea-pigging: Healthy human subjects for drug safety trials are in demand. But is it a living?. New Yorker (New York, NY: 1925), 36–41.
Fisher, J. A. (2007). Coming soon to a physician near you: Medical neoliberalism and pharmaceutical clinical drug trials. Harvard Health Policy Review: A Student Publication of the Harvard Interfaculty Initiative in Health Policy, 8(1), 61.
Fisher, J. A. (2009). Medical research for hire: The political economy of pharmaceutical clinical drug trials. New Brunswick, NJ: Rutgers University Press.
Goettlich, A. (2011). Power and powerlessness: Alfred Schutz’s theory of relevance and its possible impact on a sociological analysis of power. Civitas–Revista de Ciências Sociais, 11(3), 491–508.
Goldacre, B. (2012). Bad pharma: How drug companies mislead doctors and harm patients. London: Fourth Estate.
Horlick-Jones, T. (2005). Informal logics of risk: Contingency and modes of practical reasoning. Journal of Risk Research, 8(3), 253–272.
Kemshall, H. (1998). Risk in Probation Practice. Aldershot: Ashgate.
Kleinman, A. (1999). Moral experience and ethical reflection: Can ethnography reconcile them? A quandary for ‘the new bioethics’. Dædalus, 128(4), 69–97.
Mitchell, R., & Waldby, C. (2010). National biobanks: Clinical labor, risk production, and the creation of biovalue. Science, Technology, & Human Values, 35(3), 330–355.
Nuffield Council on Bioethics. (2011). Human bodies: Donation for medicine and research. London: Nuffield Council on Bioethics.
Petryna, A. (2005). Ethical variability: Drug development and globalizing clinical drug trials. American Ethnologist, 32(2), 183–197.
Plummer, K. (2013). Epilogue: A manifesto for a critical humanism in sociology: On questioning the human social world. In D. Nehring (Ed.), Sociology: An introductory textbook and reader (pp. 498–517). Harlow: Pearson.
Rajan, K. S. (2006). Biocapital: The constitution of postgenomic life. Durham, NC: Duke University Press.
Rose, N., & Novas, C. (2004). Biological citizenship. Oxford: Blackwell Publishing.
Schutz, A. (1970). Reflections on the problem of relevance (R. M. Zaner, Trans.). New Haven: Yale University Press.
Tutton, R. (2009). Biobanks and the inclusion of racial/ethnic minorities. Race/ Ethnicity: Multidisciplinary Global Contexts, 3(1), 75–95.
Waldby, C., & Cooper, M. (2008). The biopolitics of reproduction: Post-Fordist biotechnology and women's clinical labour. Australian Feminist Studies, 23(55), 57–73.
Will, C. M. (2011). Mutual benefit, added value? Journal of Cultural Economy, 4(1), 11–26.
Wolpe, P. R. (1998). The triumph of autonomy in American bioethics: A sociological view. In R. DeVries, & J. Subedi (Eds.), Bioethics and Society: Constructing the Ethical Enterprise (pp. 38–59). New Jersey: Prentice Hall.
Wynne, B. (1996). May the sheep safely graze? A reflexive view of the expert-lay knowledge divide. In S. Lash, B. Szerszynski, & B. Wynne (Eds.), Risk, environment and modernity: Towards a new ecoclogy. London: Sage.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2017 The Author(s)
About this chapter
Cite this chapter
Mwale, S. (2017). When Human Beings Become Guinea Pigs. In: Healthy Volunteers in Commercial Clinical Drug Trials. Palgrave Macmillan, Cham. https://doi.org/10.1007/978-3-319-59214-5_8
Download citation
DOI: https://doi.org/10.1007/978-3-319-59214-5_8
Published:
Publisher Name: Palgrave Macmillan, Cham
Print ISBN: 978-3-319-59213-8
Online ISBN: 978-3-319-59214-5
eBook Packages: Social SciencesSocial Sciences (R0)